Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood

Journal of Hematotherapy and Stem Cell Research

Volumn 11, Issue 2, 2002, Pages 277-292

  Gorin, Norbert Claude ^a,b   Piantadosi, Steven ^a   Stull, Margaret ^a   Bonte, Helene ^b   Wingard, John R ^c   Civin, Curt ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MOUSE; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RISK; T LYMPHOCYTE; TRANSPLANTATION; UMBILICAL CORD BLOOD; ANIMAL; BLOOD CELL; BONE MARROW TRANSPLANTATION; COMPARATIVE STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; INCIDENCE; LYMPHOCYTE COUNT; METHODOLOGY; MOUSE MUTANT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STANDARD; STEM CELL TRANSPLANTATION; SURVIVAL RATE; XENOGRAFT;

ANIMALS; BLOOD CELLS; BONE MARROW TRANSPLANTATION; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; LYMPHOCYTE COUNT; MICE; MICE, SCID; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK; STEM CELL TRANSPLANTATION; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0036223311     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581602753658466     Document Type: Article

References (54)

1. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling
2. Outcome of cord blood transplantation from related and unrelated donors
3. Outcomes among 562 recipients of placental-blood transplants from unrelated donors
4. Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation
5. Haematopoietic transplant potential of unrelated and related cord blood: The first six years of the EUROCORD/NETCORD Bank Germany
6. Umbilical cord blood transplant from unrelated HLA-mismatched donors in children with high risk leukemia
7. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: Analysis of engraftment and acute graft-versus-host disease
8. Umbilical cord blood: A novel alternative source of hematopoietic stem cells for bone marrow transplantation
9. Umbilical cord blood transplantation
10. Graftversus-host disease in children who have received a cordblood or bone marrow transplant from an HLA-identical sibling
11. Pathophysiology and treatment of graft-versus-host disease
12. Identification of cord blood dendritic cells as an immature CD11c-population
13. Immune responses by cord blood cells
14. The umbilical cord blood alphabeta T-cell repertoire: Characteristics of a polyclonal and naive but completely formed repertoire
15. Analysis of the cytokine production by cord and adult blood
16. Marrow grafts between DL-A matched canine littermates
17. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients
18. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
19. A prospective randomized trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies
20. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial [see comments]
21. Allogeneic peripheral blood stem cell transplantation in children with hematologic malignancies from HLA-matched siblings
22. Allogeneic peripheral blood stem cell transplantation for haematological malignancies-an analysis of kinetics of engraftment and GVHD risk
23. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors
24. Allogeneic peripheral blood progenitor cell transplantation: Analysis of short-term engraftment and acute GVHD incidence in 33 cases allo- PBPCT Spanish Group
25. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia
26. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
27. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation
28. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
29. Randomized trial of bone marrow versus lenograstimprimed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle
30. A randomised study from the european group for blood and marrow transplantation comparing allogeneic transplantation of filgrastim-mobilised peripheral blood progenitor cells with bone marrow transplantation in 350 patients (PTS) with leukemia
31. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
32. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
33. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
34. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient
35. In vivo engraftment potential of clinical hematopoietic grafts
36. Comparisons of alloreactive potential of clinical hematopoietic grafts
37. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution
38. Mature human hematopoietic cells in donor bone marrow complicate interpretation of stem/progenitor cell assays in xenogeneic hematopoietic chimeras
39. Regression models and life tables
40. Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells
41. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay
42. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice
43. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice
44. SCID mice as an in vivo model of human cord blood hematopoiesis
45. Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice
46. Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haemopoietic cells in NOD/SCID mice transplanted with human cord blood
47. Human growth factor-enhanced regeneration of transplantable human hematopoietic stem cells in nonobese diabetic/severe combined immunodeficient mice
48. Stem cell kinetics
49. + selected cells from peripheral blood
50. Treatment of highrisk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
51. Effective T cell depletion of G-CSF mobilized haploidentical PBSC graft with combined positive/negative immunomagnetic selection using Isolex 300i System Version 2.5
52. + cell selection
53. Comparison of allografts engineered by counterflow centrifugal elutriation (CCE) and CD34 selection using three immunoselection devices